Advertisement
New Zealand markets close in 13 minutes
  • NZX 50

    11,711.78
    -153.11 (-1.29%)
     
  • NZD/USD

    0.6128
    -0.0016 (-0.26%)
     
  • NZD/EUR

    0.5722
    -0.0011 (-0.20%)
     
  • ALL ORDS

    7,961.40
    -13.40 (-0.17%)
     
  • ASX 200

    7,717.90
    -6.40 (-0.08%)
     
  • OIL

    78.18
    -0.27 (-0.34%)
     
  • GOLD

    2,339.70
    -9.40 (-0.40%)
     
  • NASDAQ

    19,659.80
    +82.90 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.68 (-1.44%)
     
  • Hang Seng

    17,978.30
    +36.52 (+0.20%)
     
  • NIKKEI 225

    37,987.66
    -826.90 (-2.13%)
     
  • NZD/JPY

    96.4090
    -0.2430 (-0.25%)
     

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

LEXINGTON, Mass., May 23, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations/.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523361904/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com